EUCRISA Principal Display Panel (crisaborole) | Pfizer Medical Information - US

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PRINCIPAL DISPLAY PANEL - 60 g Tube Label

eucrisa™
(crisaborole) ointment 2%

NDC 55724-211-21
60 g
Rx only

For Topical Use Only.

Not for ophthalmic, oral, or intravaginal use.

PRINCIPAL DISPLAY PANEL - 60 g Tube Label

PRINCIPAL DISPLAY PANEL - 60 g Tube Carton

eucrisa™
(crisaborole) ointment 2%

For Topical Use Only.
Not for ophthalmic, oral, or intravaginal use.

NDC 55724-211-21

60 g
Rx only

PRINCIPAL DISPLAY PANEL - 60 g Tube Carton

PRINCIPAL DISPLAY PANEL - 60 g Tube Label - Sample

eucrisa™
(crisaborole) ointment 2%

PROFESSIONAL SAMPLE - NOT FOR SALE
NDC 55724-211-23

60 g
Rx only

For Topical Use Only.

Not for ophthalmic, oral, or intravaginal use.

PRINCIPAL DISPLAY PANEL - 60 g Tube Label - Sample

PRINCIPAL DISPLAY PANEL - 60 g Tube Carton - Sample

eucrisa™
(crisaborole) ointment 2%

PROFESSIONAL SAMPLE - NOT FOR SALE

For Topical Use Only.
Not for ophthalmic, oral, or intravaginal use.

NDC 55724-211-23

60 g
Rx only

PRINCIPAL DISPLAY PANEL - 60 g Tube Carton - Sample

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

EUCRISA Quick Finder

Pfizer samples (for eligible HCPs)

Requests for samples of prescription medications can be made by contacting Pfizer for Professionals at 1-800-505-4426 or by visiting the PfizerPro website www.pfizerpro.com.
Report an adverse event or concern about the quality of a Pfizer product

To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly by visiting www.fda.gov/medwatch or by calling (800)-332-1088.
Assistance programs (for eligible patients)

Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. Patients and physicians can contact RxPathways at (866) 706-2400 or visit the website for more information on these programs www.pfizerrxpathways.com.
Resources

Show All Hide All

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the...

Read more

Did you find an answer to your question? Yes No

1 INDICATIONS AND USAGE

EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older....

Read more

Did you find an answer to your question? Yes No

2 DOSAGE AND ADMINISTRATION

Apply a thin layer of EUCRISA twice daily to affected areas.

EUCRISA is for topical use only and not for ophthalmic, oral, or intravaginal use.

Read more

Did you find an answer to your question? Yes No

3 DOSAGE FORMS AND STRENGTHS

Ointment: 20 mg of crisaborole per gram (2%) of white to off-white ointment.

Read more

Did you find an answer to your question? Yes No

4 CONTRAINDICATIONS

EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation. [see Warnings and Precautions (5. 1)]...

Read more

Did you find an answer to your question? Yes No

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions

Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA....

Read more

Did you find an answer to your question? Yes No

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the...

Read more

Did you find an answer to your question? Yes No

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There is no available...

Read more

Did you find an answer to your question? Yes No

11 DESCRIPTION

EUCRISA contains 2% crisaborole (w/w) in a petrolatum-based, white to off-white ointment and is for topical use. The active ingredient, crisaborole, is a phosphodiesterase-4 (PDE-4) inhibitor.

...

Read more

Did you find an answer to your question? Yes No

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic...

Read more

Did you find an answer to your question? Yes No

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In an oral carcinogenicity study in Sprague-Dawley rats, oral doses of 30, 100, or...

Read more

Did you find an answer to your question? Yes No

14 CLINICAL STUDIES

Two multicenter, randomized, double-blind, parallel-group, vehicle-controlled trials (Trials 1 and 2) treated a total of 1522 subjects 2 to 79 years of age (86.3% of subjects were 2 to 17 years of age)...

Read more

Did you find an answer to your question? Yes No

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

EUCRISA is a white to off-white ointment containing 2% crisaborole and is supplied in 60 g and 100 g laminate...

Read more

Did you find an answer to your question? Yes No

17 PATIENT COUNSELING INFORMATION

Advise the patient or caregivers to read the FDA-approved patient labeling (Patient Information).

...

Read more

Did you find an answer to your question? Yes No

This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.

...

Read more

Did you find an answer to your question? Yes No

Did you find an answer to your question? Yes No

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985^*

*Contact Medical Information.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at
(800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatchor by calling
(800)-332-1088.